DK2914248T4 - Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme - Google Patents

Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme Download PDF

Info

Publication number: DK2914248T4
Authority: DK; Denmark
Prior art keywords: treatment; pharmaceutical compositions; mediated diseases; cftr mediated; cftr
Prior art date: 2012-11-02

Application number

DK13792149.0T

Other languages

English (en)

Other versions

DK2914248T3 (da

Inventor

Marinus Jacobus Verwijs

Radhika Karkare

Michael Douglas Moore

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-02

Filing date

2013-11-01

Publication date

2024-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2914248(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-11-01 Application filed by Vertex Pharma filed Critical Vertex Pharma

2018-11-26 Application granted granted Critical

2018-11-26 Publication of DK2914248T3 publication Critical patent/DK2914248T3/da

2024-01-02 Publication of DK2914248T4 publication Critical patent/DK2914248T4/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dispersion Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK13792149.0T 2012-11-02 2013-11-01 Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme DK2914248T4 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201261721622P	2012-11-02	2012-11-02
US201261728328P	2012-11-20	2012-11-20
US201361770668P	2013-02-28	2013-02-28
US201361824005P	2013-05-16	2013-05-16
US201361840668P	2013-06-28	2013-06-28
PCT/US2013/067952 WO2014071122A1 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases

Publications (2)

Publication Number	Publication Date
DK2914248T3 DK2914248T3 (da)	2018-11-26
DK2914248T4 true DK2914248T4 (da)	2024-01-02

Family

ID=50628072

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13792149.0T DK2914248T4 (da)	2012-11-02	2013-11-01	Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
DK18192504.1T DK3470063T3 (da)	2012-11-02	2013-11-01	Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK18192504.1T DK3470063T3 (da)	2012-11-02	2013-11-01	Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme

Country Status (30)

Country	Link
US (4)	US20140163068A1 (da)
EP (3)	EP4556008A3 (da)
JP (4)	JP6302923B2 (da)
KR (1)	KR102396897B1 (da)
CN (2)	CN104869982A (da)
AR (1)	AR093340A1 (da)
AU (4)	AU2013337730B2 (da)
BR (1)	BR112015009913B1 (da)
CA (1)	CA2890106C (da)
CL (1)	CL2015001148A1 (da)
CY (1)	CY1121070T1 (da)
DK (2)	DK2914248T4 (da)
ES (2)	ES2694290T5 (da)
FI (2)	FI3470063T3 (da)
HR (2)	HRP20250100T1 (da)
HU (2)	HUE039864T2 (da)
IL (2)	IL283276B2 (da)
LT (2)	LT3470063T (da)
MX (2)	MX368353B (da)
NZ (2)	NZ708474A (da)
PL (2)	PL3470063T3 (da)
PT (2)	PT2914248T (da)
RS (2)	RS66596B1 (da)
SG (3)	SG11201503365YA (da)
SI (2)	SI3470063T1 (da)
SM (2)	SMT202500078T1 (da)
TR (1)	TR201815218T4 (da)
TW (2)	TW201422253A (da)
UA (2)	UA123631C2 (da)
WO (1)	WO2014071122A1 (da)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA06002567A (es)	2003-09-06	2006-09-04	Vertex Pharma	Moduladores de transportadores con casete de union de atp.
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CN101891680B (zh)	2004-06-24	2014-10-29	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白的调控剂
ATE512145T1 (de)	2005-08-11	2011-06-15	Vertex Pharma	Modulatoren des cystic fibrosis transmembrane conductance regulators
EP2774925B1 (en)	2005-11-08	2016-12-28	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of ATP-binding cassette transporters
DK3219705T3 (da)	2005-12-28	2020-04-14	Vertex Pharma	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US7776905B2 (en)	2006-04-07	2010-08-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
WO2008141119A2 (en)	2007-05-09	2008-11-20	Vertex Pharmaceuticals Incorporated	Modulators of cftr
WO2009038913A2 (en)	2007-08-24	2009-03-26	Vertex Pharmaceuticals Incorporated	Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
HRP20140103T1 (hr)	2007-11-16	2014-05-09	Vertex Pharmaceuticals Inc.	Izokinolinski modulatori transportera atp-vežuä†e kazete
HUE031913T2 (en)	2007-12-07	2017-08-28	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
PL2231606T3 (pl)	2007-12-07	2013-07-31	Vertex Pharma	Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
JP5523352B2 (ja)	2008-02-28	2014-06-18	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
KR101727762B1 (ko)	2009-03-20	2017-04-17	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ602795A (en)	2010-04-07	2015-01-30	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RS62767B1 (sr)	2010-04-07	2022-01-31	Vertex Pharma	Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
CN105130948A (zh)	2010-04-22	2015-12-09	弗特克斯药品有限公司	制备环烷基甲酰胺基-吲哚化合物的方法
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
RU2640420C2 (ru)	2011-11-08	2018-01-09	Вертекс Фармасьютикалз Инкорпорейтед	Модуляторы транспортеров атф-связывающей кассеты
MX350788B (es)	2012-01-06	2017-09-13	Abide Therapeutics Inc	Compuestos de carbamato y preparación y uso de los mismos.
MX355183B (es)	2012-01-25	2018-04-09	Vertex Pharma	Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
JP2015511583A (ja)	2012-02-27	2015-04-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	薬学的組成物およびその投与
CA2878057A1 (en)	2012-07-16	2014-01-23	Rossitza Gueorguieva Alargova	Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SMT202500078T1 (it) *	2012-11-02	2025-03-12	Vertex Pharma	Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
US9303918B2 (en) *	2013-03-15	2016-04-05	Monosol Rx, Llc	Process for drying a wet film with control of loss on drying
US20160074374A1 (en) *	2013-04-26	2016-03-17	Vertex Pharmaceuticals Incorporated	Correctors acting through msd1 of cftr protein
HRP20210516T2 (hr)	2013-11-12	2021-10-01	Vertex Pharmaceuticals Incorporated	Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
JP6543268B2 (ja)	2014-04-15	2019-07-10	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
RS60906B1 (sr)	2014-10-06	2020-11-30	Vertex Pharma	Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
CN107250113B (zh)	2014-10-07	2019-03-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调节蛋白的调节剂的共晶
KR102576006B1 (ko)	2014-11-18	2023-09-06	버텍스 파마슈티칼스 인코포레이티드	고처리량 시험 고성능 액체 크로마토그래피의 수행 방법
US10450302B2 (en)	2015-05-11	2019-10-22	Lundbeck La Jolla Research Center, Inc.	Methods of treating inflammation or neuropathic pain
EP3352758A4 (en)	2015-09-25	2018-08-01	Vertex Pharmaceuticals (Europe) Limited	Deuterated cftr potentiators
WO2017151725A1 (en) *	2016-03-03	2017-09-08	Nivalis Therapeutics, Inc.	Formulations of an s-nitrosoglutathione reductase inhibitor
ES2946970T3 (es)	2016-03-31	2023-07-28	Vertex Pharma	Regulador de conductancia transmembrana de moduladores de fibrosis quística
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu) *	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10376501B2 (en)	2016-04-25	2019-08-13	Druggability Technologies Ip Holdco Limited	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
LT3519401T (lt)	2016-09-30	2021-11-25	Vertex Pharmaceuticals Incorporated	Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
AU2017361254B2 (en)	2016-11-16	2021-09-23	H. Lundbeck A/S.	Pharmaceutical formulations
PE20191239A1 (es)	2016-11-16	2019-09-16	Abide Therapeutics Inc	Formas cristalinas de un inhibidor de magl
PT3551622T (pt)	2016-12-09	2020-11-12	Vertex Pharma	Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
US11253509B2 (en)	2017-06-08	2022-02-22	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
CN117924170A (zh)	2017-12-01	2024-04-26	弗特克斯药品有限公司	用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
CA3085006A1 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
CA3088577A1 (en)	2018-02-15	2019-08-22	Vertex Pharmaceuticals Incorporated	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
WO2019195739A1 (en)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en)	2018-04-13	2022-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
SMT202300102T1 (it)	2018-11-14	2023-05-12	Vertex Pharma	Metodi di trattamento per la fibrosi cistica
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
US12624015B2 (en)	2019-06-24	2026-05-12	University Of Iowa Research Foundation	JNK inhibitors as anticancer agents
US11873300B2 (en)	2019-08-14	2024-01-16	Vertex Pharmaceuticals Incorporated	Crystalline forms of CFTR modulators
IL290408B2 (en)	2019-08-14	2025-10-01	Vertex Pharma	Cystic fibrosis transmembrane conductance regulator modulators
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
US11904006B2 (en)	2019-12-11	2024-02-20	University Of Iowa Research Foundation	Poly(diaminosulfide) particle-based vaccine
AU2021259496A1 (en)	2020-04-21	2022-11-10	H. Lundbeck A/S	Synthesis of a monoacylglycerol lipase inhibitor
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022036060A1 (en)	2020-08-13	2022-02-17	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
US12612416B2 (en)	2020-10-07	2026-04-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023004072A (es)	2020-10-07	2023-07-05	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
EP4225737A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373974A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL301755A (en)	2020-10-07	2023-05-01	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA3197173A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230416275A1 (en)	2020-10-07	2023-12-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL303519A (en)	2020-12-10	2023-08-01	Vertex Pharma	Cystic fibrosis treatment methods
US20240100183A1 (en) *	2020-12-11	2024-03-28	University Of Iowa Research Foundation	Compositions comprising molecules for cystic fibrosis treatment
US20240189299A1 (en) *	2021-03-09	2024-06-13	Laurus Labs Limited	Oral film of cftr modulator(s)
CA3249378A1 (en)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	TREATMENT METHODS FOR CYSTIC FIBROSIS
CN118974059A (zh)	2022-02-08	2024-11-15	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
CR20240457A (es)	2022-04-06	2024-12-11	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3253026A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	TREATMENT METHODS FOR CYSTIC FIBROSIS
JP2025530377A (ja)	2022-09-15	2025-09-11	イドルシア・ファーマシューティカルズ・リミテッド	大環状ｃｆｔｒ調節剤とｃｆｔｒコレクター及び／又はｃｆｔｒポテンシエーターとの合剤
EP4587443A1 (en)	2022-09-15	2025-07-23	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
CA3267791A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO [16,17-F]QUINOLINE-3-CARBOXAMIDE
WO2025076235A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2025186214A1 (en)	2024-03-05	2025-09-12	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
AP2005003292A0 (en)	2002-09-30	2005-06-30	Univ California	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US20050113423A1 (en)	2003-03-12	2005-05-26	Vangoor Frederick F.	Modulators of ATP-binding cassette transporters
ES2887054T3 (es)	2003-04-11	2021-12-21	Ptc Therapeutics Inc	Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
US7696244B2 (en)	2003-05-16	2010-04-13	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
ATE440825T1 (de)	2003-06-06	2009-09-15	Vertex Pharma	Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
ZA200603515B (en)	2003-10-08	2007-11-28	Vertex Pharma	Modulators of ATP-binding cassette transporters
RU2006120549A (ru)	2003-11-14	2007-12-27	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты
EA011074B1 (ru)	2004-03-30	2008-12-30	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Гидразидсодержащие соединения - ингибиторы cftr и их применение
WO2005120497A2 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
CN101891680B (zh)	2004-06-24	2014-10-29	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白的调控剂
EP1815206B1 (en)	2004-10-13	2016-04-06	PTC Therapeutics, Inc.	Compounds for nonsense suppression, and methods for their use
WO2006099256A2 (en)	2005-03-11	2006-09-21	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
JP2008538107A (ja)	2005-03-18	2008-10-09	ザリージェンツオブザユニバーシティオブカリフォルニア	変異型ｃｆｔｒプロセシングの修正において活性を有する化合物及びその用途
CA2603402C (en)	2005-04-08	2017-10-31	Ptc Therapeutics, Inc.	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
JP5426878B2 (ja)	2005-05-24	2014-02-26	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ−結合カセットトランスポーターのモジュレーター
RU2008118001A (ru)	2005-10-06	2009-11-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Модуляторы атф-зависимых транспортеров
EP2774925B1 (en)	2005-11-08	2016-12-28	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of ATP-binding cassette transporters
KR20100005730A (ko)	2007-05-07	2010-01-15	노파르티스 아게	유기 화합물
CA2699292A1 (en) *	2007-09-14	2009-03-26	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
HUE031913T2 (en) *	2007-12-07	2017-08-28	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EA017919B1 (ru)	2007-12-10	2013-04-30	Новартис Аг	Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
KR20110040818A (ko)	2008-06-10	2011-04-20	노파르티스 아게	상피 나트륨 채널 차단제로서의 피라진 유도체
KR20110042356A (ko) *	2008-08-13	2011-04-26	버텍스 파마슈티칼스 인코포레이티드	제약 조성물 및 그의 투여
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
AU2009296271A1 (en)	2008-09-29	2010-04-01	Vertex Pharmaceuticals Incorporated	Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2010256677A1 (en) *	2009-06-02	2012-01-12	Nikan Pharmaceuticals, Llc	Antagonism of human formyl peptide receptor for treatment of disease
JP2011034380A (ja) *	2009-08-03	2011-02-17	Nitto Denko Corp	タッチパネルおよびタッチパネル付表示装置
WO2011028740A1 (en)	2009-09-03	2011-03-10	Glaxo Group Limited	ENaC BLOCKERS
WO2011079087A1 (en)	2009-12-23	2011-06-30	Glaxo Group Limited	Enac blockers
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
RS62767B1 (sr) *	2010-04-07	2022-01-31	Vertex Pharma	Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
AU2011242452A1 (en) *	2010-04-22	2012-11-08	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
US10105356B2 (en) *	2011-01-31	2018-10-23	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9968607B2 (en)	2011-04-25	2018-05-15	Hetero Research Foundation	Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
MX355183B (es) *	2012-01-25	2018-04-09	Vertex Pharma	Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
SMT202500078T1 (it) *	2012-11-02	2025-03-12	Vertex Pharma	Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
HRP20210516T2 (hr) *	2013-11-12	2021-10-01	Vertex Pharmaceuticals Incorporated	Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr

2013
- 2013-11-01 SM SM20250078T patent/SMT202500078T1/it unknown
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/it unknown
- 2013-11-01 EP EP24223819.4A patent/EP4556008A3/en active Pending
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/hu unknown
- 2013-11-01 TW TW102139864A patent/TW201422253A/zh unknown
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 PL PL18192504.1T patent/PL3470063T3/pl unknown
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 PT PT13792149T patent/PT2914248T/pt unknown
- 2013-11-01 RS RS20250226A patent/RS66596B1/sr unknown
- 2013-11-01 UA UAA201803746A patent/UA123631C2/uk unknown
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/da active
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en not_active Ceased
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/pt active IP Right Grant
- 2013-11-01 HR HRP20250100TT patent/HRP20250100T1/hr unknown
- 2013-11-01 ES ES13792149T patent/ES2694290T5/es active Active
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/tr unknown
- 2013-11-01 UA UAA201505319A patent/UA117464C2/uk unknown
- 2013-11-01 ES ES18192504T patent/ES3009747T3/es active Active
- 2013-11-01 SI SI201332096T patent/SI3470063T1/sl unknown
- 2013-11-01 HU HUE18192504A patent/HUE070382T2/hu unknown
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/pl unknown
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/zh active Pending
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/zh active Pending
- 2013-11-01 MX MX2015005559A patent/MX368353B/es active IP Right Grant
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 FI FIEP18192504.1T patent/FI3470063T3/fi active
- 2013-11-01 PT PT181925041T patent/PT3470063T/pt unknown
- 2013-11-01 RS RS20181318A patent/RS57831B2/sr unknown
- 2013-11-01 SI SI201331163T patent/SI2914248T2/sl unknown
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/ja active Active
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/fi active
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/hr unknown
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/ko active Active
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/lt unknown
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/da active
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/lt unknown
- 2013-11-01 TW TW107117580A patent/TWI736768B/zh active
- 2013-11-04 AR ARP130104018A patent/AR093340A1/es not_active Application Discontinuation
2015
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/es unknown
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/es unknown
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
2016
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/ja not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/el unknown
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/ja active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/ja active Pending
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending

Also Published As

Publication number	Publication date
ES2694290T3 (es)	2018-12-19
US20140163068A1 (en)	2014-06-12
CL2015001148A1 (es)	2016-02-19
PT3470063T (pt)	2025-03-10
JP2015535289A (ja)	2015-12-10
IL283276B1 (en)	2024-01-01
BR112015009913A8 (pt)	2019-09-17
MX2015005559A (es)	2015-10-29
FI2914248T4 (fi)	2023-12-19
AU2013337730B2 (en)	2018-06-14
EP3470063B1 (en)	2025-01-01
NZ708474A (en)	2019-02-22
LT3470063T (lt)	2025-02-10
RS57831B2 (sr)	2024-02-29
EP2914248B2 (en)	2023-10-18
RS66596B1 (sr)	2025-04-30
HRP20181740T4 (hr)	2024-01-05
SI2914248T2 (sl)	2023-12-29
AU2018229528A1 (en)	2018-10-11
TWI736768B (zh)	2021-08-21
UA123631C2 (uk)	2021-05-05
CN104869982A (zh)	2015-08-26
TW201842907A (zh)	2018-12-16
US20230364073A1 (en)	2023-11-16
AU2013337730A1 (en)	2015-06-11
CA2890106C (en)	2022-08-02
RU2019117882A (ru)	2019-10-04
TW201422253A (zh)	2014-06-16
JP2022034069A (ja)	2022-03-02
FI3470063T3 (fi)	2025-03-05
HRP20250100T1 (hr)	2025-03-28
EP2914248A1 (en)	2015-09-09
AR093340A1 (es)	2015-06-03
DK3470063T3 (da)	2025-01-20
EP2914248B1 (en)	2018-09-05
US20200338063A1 (en)	2020-10-29
HRP20181740T1 (hr)	2018-12-28
LT2914248T (lt)	2018-11-26
SI2914248T1 (sl)	2018-12-31
AU2020204037A1 (en)	2020-07-09
RU2692676C2 (ru)	2019-06-26
PL3470063T3 (pl)	2025-04-14
NZ745659A (en)	2020-04-24
MX368353B (es)	2019-09-30
HUE039864T2 (hu)	2019-02-28
PT2914248T (pt)	2018-11-29
PL2914248T3 (pl)	2019-01-31
EP3470063A1 (en)	2019-04-17
BR112015009913A2 (pt)	2017-07-11
AU2024200273A1 (en)	2024-02-01
ES2694290T5 (es)	2024-05-21
WO2014071122A1 (en)	2014-05-08
KR20150080609A (ko)	2015-07-09
UA117464C2 (uk)	2018-08-10
SG10201913581UA (en)	2020-02-27
EP4556008A2 (en)	2025-05-21
IL283276A (en)	2021-07-29
BR112015009913B1 (pt)	2023-04-11
RU2015120798A (ru)	2016-12-27
AU2020204037B2 (en)	2023-10-19
SI3470063T1 (sl)	2025-04-30
JP2019142956A (ja)	2019-08-29
SG10201703452PA (en)	2017-06-29
CN111671751A (zh)	2020-09-18
DK2914248T3 (da)	2018-11-26
KR102396897B1 (ko)	2022-05-13
TR201815218T4 (tr)	2018-11-21
SMT201800590T1 (it)	2019-01-11
PL2914248T5 (pl)	2024-01-15
MX2019011662A (es)	2019-11-18
EP4556008A3 (en)	2025-08-27
JP2018090626A (ja)	2018-06-14
CA2890106A1 (en)	2014-05-08
SG11201503365YA (en)	2015-06-29
IL283276B2 (en)	2024-05-01
SMT202500078T1 (it)	2025-03-12
US20160324846A1 (en)	2016-11-10
HK1212632A1 (en)	2016-06-17
IL238551A0 (en)	2015-06-30
JP6302923B2 (ja)	2018-03-28
HUE070382T2 (hu)	2025-06-28
IL238551B (en)	2021-06-30
RS57831B1 (sr)	2018-12-31
ES3009747T3 (en)	2025-03-31
JP7003085B2 (ja)	2022-02-04
CY1121070T1 (el)	2020-05-29

Publication	Publication Date	Title
IL277470A (en)	2020-11-30	Manufacturing method for pharmaceutical preparations for the treatment of diseases caused by CFTR
LT3470063T (lt)	2025-02-10	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
DK2818482T3 (da)	2019-07-15	Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da)	2019-07-29	Farmaceutisk sammensætning til behandling af cancer
PT3030262T (pt)	2019-12-11	Composição farmacêutica de associação
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK2895156T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK2922526T3 (da)	2021-12-20	Fremstilling af semiplastiske farmaceutiske doseringsenheder
DK3378862T3 (da)	2022-04-11	Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
PT2854768T (pt)	2017-05-19	Composições farmacêuticas de pemetrexed
DK3116491T3 (da)	2021-08-09	Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
HUE037179T2 (hu)	2018-08-28	Gyógyászati kompozíciók izom-rendellenességek kezelésére
DK2897594T3 (da)	2020-06-29	Farmaceutisk sammensætning
DK2939665T3 (da)	2019-06-11	Farmaceutisk sammensætning til behandling af hiv-infektioner
IL234606B (en)	2021-04-29	Novel methods and composition for treatment of disease
DK3524260T3 (da)	2023-10-09	Farmaceutiske sammensætninger til behandling af manglende appetit
DK2892556T3 (da)	2019-08-05	Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2900259T3 (da)	2020-07-13	Glycosidase-regime til behandling af infektionssygdomme
DK2705847T3 (da)	2014-10-06	Sammensætning til behandling af psoriasis
DK2928454T3 (da)	2020-03-30	Triaziner til behandling af protozosygdomme
IL238592B (en)	2018-04-30	Compounds for treatment of liver diseases
DK2828396T3 (da)	2019-05-27	Fremgangsmåde til fremstillingen af g-csf
DK2814462T3 (da)	2017-11-27	Oliebaseret farmaceutisk sammensætning til behandling af gastrointestinale sygdomme
EP2897590A4 (en)	2016-05-04	PHARMACEUTICAL COMPOSITION